( The safety profile of liraglutide in our cohort was consistent with previous pediatric randomized controlled trials (RCTs), with adverse events (AEs) predominantly mild and gastrointestinal in nature, including nausea, vomiting, and diarrhea, reported in 43.6% of participants ( Despite these favorable outcomes, the discontinuation rate during the dose-escalation phase was relatively high (25.6%), mirroring patterns observed in other pediatric liraglutide trials where treatment withdrawal often occurred during the initial weeks, coinciding with peak gastrointestinal symptoms ( A key strength of this study lies in its conduct within a publicly funded healthcare system, entirely independent of pharmaceutical industry sponsorship, thereby enhancing both methodological rigor and external validity
9X 11.1g (370mgX30)
doi:10.1007/978-3-030-28929-4_2
Within preclinical and in-vitro experimental systems, it is used to analyze receptor co-activation, downstream signal-transduction dynamics, and pathway-level coordination without clinical or therapeutic intent
In ischaemic rats, BPC 157 was administered during reperfusion
.png)
